Biospecimen Access

NRG Oncology Biospecimen Access

The NRG Oncology Biospecimen Bank is the central repository and reference laboratory for biospecimens collected from patients enrolled in Phase II and III NRG Oncology clinical cancer trials. This collection includes but is not limited to unstained slides, paraffin-embedded tissue blocks, frozen tissues, and biofluids such as blood, plasma, serum, and buffy coats. All biospecimens are from patients enrolled in NRG Oncology clinical trials and in the legacy group trials of NSABP, RTOG, and GOG. Extensive clinical and outcome data exists for most of these biospecimens and is stored in the statistical data center.

The Biospecimen Bank provides annotated, de-identified, and if required, anonymized biospecimens to qualified investigators who comply with National Cancer Institute (NCI) National Clinical Trials Network (NCTN) Banks’ access policies and who have funding to support their project (

All requests for biospecimens must be approved by the NCTN Core Correlative Sciences Committee (NCTN-CCSC). Since NCTN CCSC approval is required before biospecimens can be distributed, investigators are encouraged to submit their requests to NRG Oncology prior to submission of research grants or requests to a funding agency.  This early submission is intended to assure the investigator that the required biospecimens are available for their project. 

Instructions for Application Submission

  1. It is strongly recommended that investigators research the availability of biospecimens through the website and by directly contacting the NRG Oncology Biospecimen Bank prior to submitting the feasibility form.
  2. Complete the Feasibility Query Form and submit it to NRG Oncology at Once received, NRG Oncology will assign a staff member to work with the investigator throughout the review process. 
  3. The Feasibility Query will be reviewed by NRG Oncology staff. The investigator will be provided with a preliminary evaluation of the overall feasibility of the project including specimen availability and the appropriateness of the research question. 
  4. If the proposal is determined to be feasible, the investigator will be instructed to complete the NCTN CCSC Proposal Submission Form and submit it along with all letters of collaboration to NRG Oncology will review the proposal, and upon approval, staff will work with the investigator, as appropriate, to refine the application prior to submission to the NCTN-CCSC for review and approval.
  5. The NCTN-CCSC will review the application for scientific merit and alignment with the goals of the NCTN.  The NCTN-CCSC will provide written comments of their review.   
  6. If the application is approved by the NCTN-CCSC the investigator will work with NRG Oncology staff to complete the regulatory and legal documentation needed prior to distribution of biospecimens. The documentation required includes:
  • Institutional Review Board (IRB)/Ethics Committee (EC) review/approval notification from the investigator’s institution
  • Material Transfer Agreement (MTA)       
  • Funding commitment (There must be sufficient funds available to the investigator to cover the expenses related to the accession and distribution of biospecimens.  The total cost with further details will be provided by the NRG Oncology Biospecimen Bank on inquiry from the investigator.)       
  • Data Transfer Agreement (DTA), if appropriate, for the transfer of clinical data

NOTE: Investigators are required to notify NRG Oncology of any publications that result from the use of biospecimens. For more information about the NRG Oncology Biospecimen Bank please email


Copyright 2018 by NRG Oncology